MSD has fleshed out the results of phase 3 trials of its cholesterol-lowering, oral PCSK9 inhibitor, enlicitide decanoate, showing its efficacy was comparable to that of injectable alternatives. The ...
Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.
A pill from Structure Therapeutics Inc. helped patients lose roughly as much weight as a rival treatment from Eli Lilly & Co., giving the startup an edge as it seeks to break into the highly ...
In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables. The results from two phase ...
NEW ORLEANS, LA—Use of enlicitide 20 mg, an oral PCSK9 inhibitor, significantly cut levels of LDL cholesterol and other atherogenic lipids in a large cohort of high-risk patients, results from the ...
NEW ORLEANS — Like the injectable therapies that came before, an oral once-daily PCSK9 inhibitor appears to generate profound reductions in LDL cholesterol (LDL-C), new data show, a result that ...
Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibition demonstrated benefit in the broader primary prevention population for LDL lowering and plaque ...
Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine hairpins, they increased cholesterol uptake by cells and reduced ...
Merck, known as MSD outside of the United States and Canada, announced positive topline results from the phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate, an ...
Lilly will acquire Verve Therapeutics and a pipeline of one-time treatments for cardiovascular diseases in a deal worth up to US$1.3 billion. "In just seven years, our team has progressed three in ...
When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the arteries and cardiovascular health. Now, a study led by the University of ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback